Schizophrenia trials in China: a survey

Chakrabarti, Anannya; Adams, Clive E; Rathbone, John; Wright, Judy; Xia, Jun; Wong, Winson; Reibnitz, P. Von; Koenig, Carolin; Baier, Stephan; Pfeiffer, Christine M.; Blatter, J.; Mantz, Michael B.; Kloeckner, K.

doi:10.1111/j.1600-0447.2007.01027.x

Cited by 10 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CSG has recently repeated this exercise for schizophrenia trials for particular regions of the world. 33 When CSG collaborators have used the register of trials to investigate aspects of evaluative research in this area to more depth, they have found worrying signs. For example, it seems that 40% of outcomes in schizophrenia trials are based on scales not validated at their time of use.…”

Section: Direct Contributions To the Science Of Reviewingmentioning

confidence: 99%

Cochrane Schizophrenia Group

Adams

Coutinho

Davis

et al. 2007

Schizophrenia Bulletin

Self Cite

View full text Add to dashboard Cite

Section: Direct Contributions To the Science Of Reviewingmentioning

confidence: 99%

Cochrane Schizophrenia Group

Adams

Coutinho

Davis

et al. 2007

Schizophrenia Bulletin

Self Cite

View full text Add to dashboard Cite

“…In the following decades, the interest in course studies increased [7-10] and different trends emerged, not necessarily chronic, but dynamic, evolving and subject to change [11-13], with the possibility of remission [14]. …”

Section: Introductionmentioning

confidence: 99%

Schizophrenia in real life: courses, symptoms and functioning in an Italian population

Turola¹,

Comellini²,

Galuppi

et al. 2012

Int J Ment Health Syst

View full text Add to dashboard Cite

BackgroundIn the general belief, schizophrenia is associated with the concepts of seriousness, incurability, dangerousness: this is incorrect. In recent decades, the interest in course studies increased and different trends emerged, not necessarily chronic, with the possibility of remission.The plan of this research was to draw a picture of the schizophrenia syndrome in a specific geographic area, in the past and at present time: this allows to detect needs, weaknesses and strengths, for a better planning of future interventions.MethodsThe course of all cases diagnosed as schizophrenia (N = 1,759) in the period 1978–2008, was retrospectively studied in the entire population of an Italian province by observing, for a mean period of 12 years per person, age at first psychiatric consultation, number and length of admissions for both acute symptoms and residential-rehabilitation programs, number of interventions in outpatients. The cases under treatment (N = 842), were evaluated in terms of symptoms, using the Brief Psychiatric Rating Scale, and in terms of functioning, using the Personal and Social Functioning Scale.ResultsThe disease course differs significantly between genders: males have an earlier age at first consultation (about 7 years earlier), higher admission rates, greater number of outpatient interventions and personal and social functioning significantly worse.Hospitalization resulted often unnecessary: 23.1% of cases were never hospitalized and 67.2% spent less than one week per year in hospital.A quarter of the cases meets the international criteria for remission and more than 75% are asymptomatic or mildly symptomatic; only 5.3% of cases shows severe symptoms. However, Personal and Social Functioning highlights, in about 1/3 of cases, relevant or serious problems mainly in Work and Relationships areas, whilst Aggressiveness is a serious problem only in 9%.ConclusionsIn this population, schizophrenia in real life shows great individual variability in course, symptoms and functioning: in most cases nowadays it appears a less severe and chronic disease than in the past, but further improvements are needed on disability prevention and social inclusion.

show abstract

“…As an antipsychotic drug of the benzamide class, sulpiride is mainly used in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression [1,2,3]. Recently, schizophrenia has a significant rise with China’s economic booming, thus sulpiride is widely used in clinical applications and administrated in large dose for typical acute treatment [1,4,5,6,7]. In addition, sulpiride as a relative old antipsychotic drug is more cost-effective than newer drugs in developing countries, and also has had other uses including treatment of peptic ulcer, vomiting and vertigo.…”

Section: Introductionmentioning

confidence: 99%

Preparation, Characterization and Application of a Molecularly Imprinted Polymer for Selective Recognition of Sulpiride

et al. 2017

View full text Add to dashboard Cite

A novel molecular imprinting polymer (MIP) was prepared by bulk polymerization using sulpiride as the template molecule, itaconic acid (ITA) as the functional monomer and ethylene glycol dimethacrylate (EGDMA) as the crosslinker. The formation of the MIP was determined as the molar ratio of sulpiride-ITA-EGDMA of 1:4:15 by single-factor experiments. The MIP showed good adsorption property with imprinting factor α of 5.36 and maximum adsorption capacity of 61.13 μmol/g, and was characterized by scanning electron microscopy (SEM), Fourier-transform infrared spectroscopy (FT-IR) and surface area analysis. With the structural analogs (amisulpride, tiapride, lidocaine and cisapride) and small molecules containing a mono-functional group (p-toluenesulfonamide, formamide and 1-methylpyrrolidine) as substrates, static adsorption, kinetic adsorption, and rebinding experiments were also performed to investigate the selective adsorption ability, kinetic characteristic, and recognition mechanism of the MIP. A serial study suggested that the highly selective recognition ability of the MIP mainly depended on binding sites provided by N-functional groups of amide and amine. Moreover, the MIP as solid-phase extractant was successfully applied to extraction of sulpiride from the mixed solution (consisted of p-toluenesulfonamide, sulfamethoxazole, sulfanilamide, p-nitroaniline, acetanilide and trimethoprim) and serum sample, and extraction recoveries ranged from 81.57% to 86.63%. The tentative tests of drug release in stimulated intestinal fluid (pH 6.8) demonstrated that the tablet with the MIP–sulpiride could obviously inhibit sulpiride release rate. Thus, ITA-based MIP is an efficient and promising alternative to solid-phase adsorbent for extraction of sulpiride and removal of interferences in biosample analysis, and could be used as a potential carrier for controlled drug release.

show abstract

Schizophrenia trials in China: a survey

Abstract: Introduction: China's biomedical research activity is increasing and this literature is

Cited by 10 publications

References 13 publications

Cochrane Schizophrenia Group

Cochrane Schizophrenia Group

Schizophrenia in real life: courses, symptoms and functioning in an Italian population

Preparation, Characterization and Application of a Molecularly Imprinted Polymer for Selective Recognition of Sulpiride

Contact Info

Product

Resources

About